Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Mercury Pharma Group
No. 1 Croydon, 12 - 16 Addiscombe Road, Croydon, Surrey, CR0 0XT, UK
Telephone: +44 (0)208 588 9100
Fax: +44 (0)208 686 0807
WWW: http://www.mercurypharma.com
Medical Information Direct Line: 08700 70 30 33
Medical Information e-mail: medicalinformation@mercurypharma.com
Customer Care direct line: +44 (0)208 588 9273
Medical Information Fax: +44 (0)208 686 0807

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 25/11/2010
SPC Levothyroxine 100mcg tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 25/11/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
Date of revision of text on the SPC:   01-Nov-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.4: waring about use in patients with cardiovasular conditions, Sugar intolerance has been added. warning about use in elderly patients, hypothyroidism has been added. Use in patients with thyroid replacement has been added. A sepacial warning on hair loss and its use in elderly patients has been added. aspecial precaution to prevent bone loss has been added.

Section 4.5: The interaction with drugs has been arranged in order and some new interactions have been added.

Section 4.8:This section has been arranged as per SOC and new side-effects have been added.

Section 4.9: This section has been divided into 2 parts i.e. symptoms and treatment and new treatment methods have been introduced. 
Updated on 13/09/2010 and displayed until 25/11/2010
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
Date of revision of text on the SPC:   02-Sep-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company


National Bulk Type IB category C.I.3 a variation to update section 4.2 of the SmPC for inclusion of paediatric information in line with the European agreements as per MHRA letter dated 17 May 2010.
Updated on 08/09/2010 and displayed until 13/09/2010
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
Date of revision of text on the SPC:  
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
None provided

Active Ingredients/Generics

 
  levothyroxine sodium